Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Oo C, Sy SKB. Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective. Drug Discov Today. 2020;25(1):1–3.

PubMed  Article  Google Scholar 

Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust. 1970;2(20):923–4.

CAS  PubMed  Article  Google Scholar 

Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857–68.

CAS  PubMed  Article  Google Scholar 

Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhao M, Wu XJ, Fan YX, Zhang YY, Guo BN, Yu JC, et al. Pharmacokinetics of colistin methanesulfonate (CMS) in healthy Chinese subjects after single and multiple intravenous doses. Int J Antimicrob Agents. 2018;51(5):714–20.

CAS  PubMed  Article  Google Scholar 

Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643.

PubMed  PubMed Central  Article  Google Scholar 

Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303.

PubMed  PubMed Central  Article  Google Scholar 

Sopirala MM, Pope-Harman A, Nunley DR, Moffatt-Bruce S, Ross P, Martin SI. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant. 2008;27(7):804–7.

PubMed  Article  Google Scholar 

Lagana P, Melcarne L, Delia S. Acinetobacter baumannii and endocarditis, rare complication but important clinical relevance. Int J Cardiol. 2015;187:678–9.

CAS  PubMed  Article  Google Scholar 

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017;72(5):1415–20.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Menegucci TC, Fedrigo NH, Lodi FG, Albiero J, Nishiyama SAB, Mazucheli J, et al. Pharmacodynamic effects of sulbactam/meropenem/polymyxin-B combination against extremely drug resistant Acinetobacter baumannii using checkerboard information. Microb Drug Resist. 2019;25(9):1266–74.

CAS  PubMed  Article  Google Scholar 

Ooi MH, Ngu SJ, Chor YK, Li J, Landersdorfer CB, Nation RL. Population pharmacokinetics of intravenous colistin in pediatric patients: implications for the selection of dosage regimens. Clin Infect Dis. 2019;69(11):1962–8.

CAS  PubMed  Article  Google Scholar 

Blumer JL, Reed MD, Kearns GL, Jacobs RF, Gooch WM 3rd, Yogev R, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother. 1995;39(8):1721–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schaad UB, Guenin K, Straehl P. Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients. Rev Infect Dis. 1986;8(Suppl. 5):S512–7.

PubMed  Article  Google Scholar 

US FDA. Coly-Mycin® M parenteral colistimethate for injection, USP. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050108s033lbl.pdf. Accessed 29 Jul 2022.

US FDA. Merrem® IV (meropenem for injection), for intravenous use. 1996. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s037lbl.pdf. Accessed 29 Jul 2022.

Nahata MC, Vashi VI, Swanson RN, Messig MA, Chung M. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Antimicrob Agents Chemother. 1999;43(5):1225–9.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol. 2013;14(2): e63.

Article  CAS  Google Scholar 

Sy SK, Wang X, Derendorf H. Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics. In: Derendorf H, Schmidt S, editors. Applied pharmacometrics. New York: Springer; 2014. p. 1–64.

Google Scholar 

Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238–57.

CAS  PubMed  Article  Google Scholar 

Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259–76.

CAS  PubMed  Article  Google Scholar 

Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother. 1989;24(Suppl. A):125–32.

CAS  PubMed  Article  Google Scholar 

Park SW, We JS, Kim GW, Choi SH, Park HS. Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I). Antimicrob Agents Chemother. 2002;46(2):575–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ikawa K, Nakashima A, Morikawa N, Ikeda K, Murakami Y, Ohge H, et al. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment. Antimicrob Agents Chemother. 2011;55(12):5609–15.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ganguly S, Edginton AN, Gerhart JG, Cohen-Wolkowiez M, Greenberg RG, Gonzalez D, et al. Physiologically based pharmacokinetic modeling of meropenem in preterm and term infants. Clin Pharmacokinet. 2021;60(12):1591–604.

CAS  PubMed  Article  Google Scholar 

Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989;24(Suppl. A):311–20.

CAS  PubMed  Article  Google Scholar 

Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S. Stability of meropenem after reconstitution for administration by prolonged infusion. Hosp Pharm. 2019;54(3):190–6.

CAS  PubMed  Article  Google Scholar 

Nakwan N, Usaha S, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pharmacokinetics of colistin following a single dose of intravenous colistimethate sodium in critically ill neonates. Pediatr Infect Dis J. 2016;35(11):1211–4.

PubMed  Article  Google Scholar 

Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011;1(1):30.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–41.

CAS  PubMed  Article  Google Scholar 

Honore PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif. 2014;37(4):291–5.

CAS  PubMed  Article  Google Scholar 

Ma Z, Wang J, Nation RL, Li J, Turnidge JD, Coulthard K, et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother. 2009;53(7):2857–64.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bouchene S, Marchand S, Couet W, Friberg LE, Gobin P, Lamarche I, et al. A whole-body physiologically based pharmacokinetic model for colistin and colistin methanesulfonate in rat. Basic Clin Pharmacol Toxicol. 2018;123(4):407–22.

CAS  PubMed  Article  Google Scholar 

Viel A, Henri J, Bouchene S, Laroche J, Rolland JG, Manceau J, et al. A population WB-PBPK model of colistin and its prodrug CMS in pigs: focus on the renal distribution and excretion. Pharm Res. 2018;35(5):92.

PubMed  Article  CAS  Google Scholar 

Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–6.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Sharma VD, Singla A, Chaudhary M, Taneja M. Population pharmacokinetics of fixed dose combination of ceftriaxone and sulbactam in healthy and infected subjects. AAPS PharmSciTech. 2016;17(5):1192–203.

CAS  PubMed  Article  Google Scholar 

Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, Sukarnjanaset W, Samaeng M, Nawakitrangsan M, et al. Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(12):7236–44.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Foulds G, Stankewich JP, Marshall DC, O’Brien MM, Hayes SL, Weidler DJ, et al. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother. 1983;23(5):692–9.

CAS  PubMed  PubMed Central  Article 

留言 (0)

沒有登入
gif